2. Brief information about company and project
2
ASINEX Medkhim.
is a private company aimed at the development of
innovative medicines for the treatment of orphan and other
diseases, that are serious medical and social problems, for
which there are not effective means of treatment
The company was founded in 2001
ASINEX Medkhim. have the status of Skolkovo Participant and
earned a Rub 40 million of grant for this project implementation
The project
is aimed at the development of medicines for the treatment of
primary and secondary malignant neoplasms in central
nervous system.
3. Brain cancer and brain metastases:
The global health problem
20% of all cancer deaths
No effective treatment at the moment: no cure, high price
The main problem is low blood-to-brain barrier (BBB) penetration of the majority
of anticancer drugs 3
Malignant neoplasms in the central nervous system and primarily in brain are
deadly diseases with poor prognosis for patients.
Primary tumors
In adults 1,5%
In children 20%
Secondary tumors (metastases to
CNS)*
20 – 45%
Brain tumor incidences (% of total tumor cases)
* WHO expects 15 millions new cases of cancer annually to 2020 (approximately 3-7 million cases of
brain metastases)
Length of life of patients with malignant brain tumor
10% patients only – 5 and more years
Glioblastoma multiform – 12-14 months
4. 4
We offer for partner development a technical
solution that
effectively resolves the problem of BBB
permeability
of novel targeted anticancer drugs
5. Global drug market for brain tumors
5
Big and middle-size Pharma companies from
USA, EU and Japan.
The market for therapy of brain cancer is much bigger than $ 5 billion with a
tendency for a significant growth in the mid-term
Annual sales of Temodal, million $
121
180
278 324
459
588
703
861
1002 1073 1065
935
2000 01 02 03 04 05 06 07 08 09 10 11
Our project:
• yearly sales: $ 100-150 million
• up to 1 billion dollars after 5-6 years
• 20% market share.
Our business models:
out-licensing of projects after the
completion of Phase I/II of clinical
trials.
• > $ 5 billions rapidly growing global market
6. Our Solution
6
• We have developed several classes of novel patentable inhibitors of
oncogenic thyrosine kinases (VEGFR-2, EGFR, HER2+)
• Some lead compounds are capable of effectively penetrating through the
BBB and show antitumor efficacy in animal models of brain tumors
0
500
1000
1500Brain
To Plasma
%
survival of animals
Lapatinib; Sunitinib; AGB-01; AGB-02; Temodal
Intellectual property (IP):
• “Novel kinase inhibitors”, № 2011122942, priority date 08.06.2011
• РСТ/RU2012/000428, filing date 31.05.2013
7. Dmitry Genis, CEO, co-investor of the project.
strategic management of the company, human resource policy, financial
management. Search for and recruitment of additional sources of finance.
Development and control for business-plan realization.
Denis Kazyulkin, Deputy CEO
Day-to-day management, composing comprehensive R&D
plans, supervision and R&D execution.
Natalya Vasilevich, Head of medicinal chemistry group
Direct supervision of the group of medicinal chemists. Supervision of the
execution of work in cooperating organizations. Writing current reports
and composing patent applications.
Olga Lebedeva, Coordinator of R&D and pre-clinical study
Coordination of study of biological activity of chemical compounds within
the company. Maintenance and creation of business contacts with external
contract organizations, scientific and business consultants. IP portfolio
management.
Project team
7
8. Required support
We require additional funding to advance the medicinal
chemistry hit-to lead program and for preliminary evaluation
of anticancer potential of prospective compounds.
In accordance with our estimations we need
about $ 3 million during 2.5 years
for the completion of preclinical development.
For the second stage of project (Phase I-II of clinical trials)
we require $ 4-5 million.
Business and scientific expertise.
8
